S&P 500   3,782.74 (+2.84%)
DOW   30,255.45 (+2.59%)
QQQ   281.14 (+2.78%)
AAPL   145.68 (+2.27%)
MSFT   247.92 (+2.98%)
META   139.94 (+0.96%)
GOOGL   101.23 (+2.63%)
AMZN   120.76 (+4.21%)
TSLA   247.96 (+2.29%)
NVDA   131.16 (+4.83%)
NIO   16.66 (+7.55%)
BABA   84.03 (+4.45%)
AMD   67.84 (+2.62%)
T   16.04 (+0.88%)
MU   53.87 (+4.16%)
CGC   3.12 (+7.22%)
F   12.29 (+7.15%)
GE   67.19 (+5.64%)
DIS   100.78 (+3.76%)
AMC   7.80 (+13.37%)
PYPL   92.60 (+6.22%)
PFE   44.33 (+0.43%)
NFLX   239.00 (-0.02%)
S&P 500   3,782.74 (+2.84%)
DOW   30,255.45 (+2.59%)
QQQ   281.14 (+2.78%)
AAPL   145.68 (+2.27%)
MSFT   247.92 (+2.98%)
META   139.94 (+0.96%)
GOOGL   101.23 (+2.63%)
AMZN   120.76 (+4.21%)
TSLA   247.96 (+2.29%)
NVDA   131.16 (+4.83%)
NIO   16.66 (+7.55%)
BABA   84.03 (+4.45%)
AMD   67.84 (+2.62%)
T   16.04 (+0.88%)
MU   53.87 (+4.16%)
CGC   3.12 (+7.22%)
F   12.29 (+7.15%)
GE   67.19 (+5.64%)
DIS   100.78 (+3.76%)
AMC   7.80 (+13.37%)
PYPL   92.60 (+6.22%)
PFE   44.33 (+0.43%)
NFLX   239.00 (-0.02%)
S&P 500   3,782.74 (+2.84%)
DOW   30,255.45 (+2.59%)
QQQ   281.14 (+2.78%)
AAPL   145.68 (+2.27%)
MSFT   247.92 (+2.98%)
META   139.94 (+0.96%)
GOOGL   101.23 (+2.63%)
AMZN   120.76 (+4.21%)
TSLA   247.96 (+2.29%)
NVDA   131.16 (+4.83%)
NIO   16.66 (+7.55%)
BABA   84.03 (+4.45%)
AMD   67.84 (+2.62%)
T   16.04 (+0.88%)
MU   53.87 (+4.16%)
CGC   3.12 (+7.22%)
F   12.29 (+7.15%)
GE   67.19 (+5.64%)
DIS   100.78 (+3.76%)
AMC   7.80 (+13.37%)
PYPL   92.60 (+6.22%)
PFE   44.33 (+0.43%)
NFLX   239.00 (-0.02%)
S&P 500   3,782.74 (+2.84%)
DOW   30,255.45 (+2.59%)
QQQ   281.14 (+2.78%)
AAPL   145.68 (+2.27%)
MSFT   247.92 (+2.98%)
META   139.94 (+0.96%)
GOOGL   101.23 (+2.63%)
AMZN   120.76 (+4.21%)
TSLA   247.96 (+2.29%)
NVDA   131.16 (+4.83%)
NIO   16.66 (+7.55%)
BABA   84.03 (+4.45%)
AMD   67.84 (+2.62%)
T   16.04 (+0.88%)
MU   53.87 (+4.16%)
CGC   3.12 (+7.22%)
F   12.29 (+7.15%)
GE   67.19 (+5.64%)
DIS   100.78 (+3.76%)
AMC   7.80 (+13.37%)
PYPL   92.60 (+6.22%)
PFE   44.33 (+0.43%)
NFLX   239.00 (-0.02%)
NASDAQ:DMAC

DiaMedica Therapeutics - DMAC Stock Forecast, Price & News

$1.23
-0.01 (-0.81%)
(As of 10/4/2022 02:54 PM ET)
Add
Compare
Today's Range
$1.23
$1.24
50-Day Range
$1.20
$1.97
52-Week Range
$1.15
$4.80
Volume
94 shs
Average Volume
68,581 shs
Market Capitalization
$32.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

DiaMedica Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
713.0% Upside
$10.00 Price Target
Short Interest
Healthy
0.43% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.92mentions of DiaMedica Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$276,605 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.59) to ($0.83) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.07 out of 5 stars

Medical Sector

622nd out of 1,087 stocks

Pharmaceutical Preparations Industry

295th out of 546 stocks

DMAC stock logo

About DiaMedica Therapeutics (NASDAQ:DMAC) Stock

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Receive DMAC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DiaMedica Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

DMAC Stock News Headlines

DiaMedica Therapeutics Inc DMAC Stock Chart
DiaMedica Therapeutics Inc. (DMAC)
See More Headlines
Receive DMAC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DiaMedica Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

DMAC Company Calendar

Last Earnings
8/10/2022
Today
10/04/2022
Next Earnings (Estimated)
11/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DMAC
Fax
N/A
Employees
14
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.00
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+713.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-13,590,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.67 per share

Miscellaneous

Free Float
24,962,000
Market Cap
$32.52 million
Optionable
Not Optionable
Beta
2.08

Key Executives

  • Mr. Dietrich John Pauls MBAMr. Dietrich John Pauls MBA (Age 51)
    Pres, CEO & Director
    Comp: $684.09k
  • Mr. Scott B. Kellen C.A. (Age 57)
    CFO & Company Sec.
    Comp: $391.72k
  • Dr. Edward G. Calamai Ph.D.
    Consulting Head of Manufacturing
  • Dr. Kirsten L. Gruis M.D. (Age 49)
    M.S., Chief Medical Officer
  • Mr. Dominic R. Cundari (Age 71)
    Chief Commercial Officer
  • Ms. Julie VanOrsdel Daves CCRP
    Sr. VP of Clinical Devel. Operations













DMAC Stock - Frequently Asked Questions

Should I buy or sell DiaMedica Therapeutics stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for DiaMedica Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" DMAC shares.
View DMAC analyst ratings
or view top-rated stocks.

What is DiaMedica Therapeutics' stock price forecast for 2022?

3 equities research analysts have issued 1-year price targets for DiaMedica Therapeutics' stock. Their DMAC share price forecasts range from $8.00 to $12.00. On average, they expect the company's stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 706.5% from the stock's current price.
View analysts price targets for DMAC
or view top-rated stocks among Wall Street analysts.

How have DMAC shares performed in 2022?

DiaMedica Therapeutics' stock was trading at $3.73 at the beginning of 2022. Since then, DMAC shares have decreased by 66.8% and is now trading at $1.24.
View the best growth stocks for 2022 here
.

When is DiaMedica Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our DMAC earnings forecast
.

How were DiaMedica Therapeutics' earnings last quarter?

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) posted its quarterly earnings results on Wednesday, August, 10th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.16) by $0.03.

What other stocks do shareholders of DiaMedica Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DiaMedica Therapeutics investors own include VBI Vaccines (VBIV), Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Pfizer (PFE), Vaxart (VXRT), Aldeyra Therapeutics (ALDX), Capricor Therapeutics (CAPR), Oncolytics Biotech (ONCY), Sesen Bio (SESN) and Sorrento Therapeutics (SRNE).

When did DiaMedica Therapeutics IPO?

(DMAC) raised $18 million in an IPO on Friday, December 7th 2018. The company issued 4,000,000 shares at $4.00-$5.00 per share. Craig-Hallum Capital Group acted as the underwriter for the IPO.

What is DiaMedica Therapeutics' stock symbol?

DiaMedica Therapeutics trades on the NASDAQ under the ticker symbol "DMAC."

How do I buy shares of DiaMedica Therapeutics?

Shares of DMAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is DiaMedica Therapeutics' stock price today?

One share of DMAC stock can currently be purchased for approximately $1.24.

How much money does DiaMedica Therapeutics make?

DiaMedica Therapeutics (NASDAQ:DMAC) has a market capitalization of $32.79 million. The company earns $-13,590,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis.

How can I contact DiaMedica Therapeutics?

DiaMedica Therapeutics' mailing address is 2 CARLSON PARKWAY SUITE 260, MINNEAPOLIS MN, 55447. The official website for the company is www.diamedica.com. The company can be reached via phone at (763) 312-6755 or via email at skellen@diamedica.com.

This page (NASDAQ:DMAC) was last updated on 10/4/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.